Answers are grounded in this paper and cite their sources.
Two novel iridium-europium bimetallic complexes, {[(dfppy)2Ir(mu-phen5f)]3EuCl}Cl2 and (dfppy)2Ir(mu-phen5f)Eu(TFAcA)3 [dfppy represents 2-(4',6'-difluorophenyl)-pyridinato-N,C(2'), phen5f stands for 4,4,5,5,5-pentafluoro-1-(1',10'-phenanthrolin-2'-yl)-pentane-1,3-dionate and TFAcA represents trifluoroacetylacetonate], were successfully synthesized. The novel ligand Hphen5f with four coordination sites was designed as a bridge to link the Ir (III) center and the Eu (III) center. The X-ray diffraction data shows that the nonbonding distances for Eu...Ir are 6.028, 5.907, and 6.100 A in the bimetallic complex {[(dfppy)2Ir(mu-phen5f)]3EuCl}Cl2. Photophysical studies implied that the high efficient red luminescence from the Eu (III) ion was sensitized by the (3)MLCT (metal-to-ligand charge transfer) energy based on an Ir (III) complex-ligand in a d-f bimetallic assembly. The excitation window for the new bimetallic complex {[(dfppy)2Ir(mu-phen5f)]3EuCl}Cl2 extends up to 530 nm (1 x 10(-3) M in EtOH), indicating that this bimetallic complex can emit red light under the irradiation of sunlight.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: